Introduction: The Disconnect Between Surgical Success and Patient Satisfaction
Every surgeon has experienced this frustrating scenario: a technically perfect cataract extraction with an excellent refractive outcome, yet the patient complains of blurry vision, foreign body sensation, and persistent discomfort. The intraocular lens is perfectly positioned, the cornea is clear, and the retina is healthy—but the patient is miserable and contemplating legal action. What went wrong?
The answer often lies not in what was done during surgery, but in what was overlooked before it: the meibomian glands and the critical oil layer they produce.[1][2][3]
The Scope of the Problem: Dry Eye Disease and Surgical Outcomes
Dry eye disease (DED) affects up to 60% of patients presenting for ocular surgery, yet it remains dramatically underdiagnosed and undertreated in the preoperative setting.[2] The consequences of this oversight are profound. Despite achieving excellent anatomical and refractive outcomes, surgeons face dissatisfied patients whose quality of life is significantly impaired by postoperative ocular surface dysfunction.[4][5]
The most common postoperative complaints—foreign body sensation, blurry vision, pain, and visual fluctuation—are frequently not complications of the surgery itself, but rather manifestations of undiagnosed or undertreated meibomian gland dysfunction (MGD).[1][2][6] Patients who were asymptomatic preoperatively may develop severe symptoms postoperatively, while those with pre-existing MGD experience dramatic worsening of their condition.[7][6]
The Critical Role of Meibomian Glands: Understanding the Oil Layer
Meibomian glands produce the lipid layer of the tear film, which prevents excessive evaporation and maintains tear film stability.[8][9] When these glands are dysfunctional or atrophied, the tear film becomes unstable, leading to evaporative dry eye—the most common form of DED.[10][8] This lipid deficiency creates a cascade of problems: increased tear osmolarity, ocular surface inflammation, epithelial damage, and ultimately, visual disturbances and discomfort.[6][11]
The importance of this oil layer cannot be overstated. Without adequate lipid coverage, even patients with normal aqueous tear production will experience symptomatic dry eye.[8][9] This explains why many postoperative patients complain of symptoms despite having "wet-looking" eyes or adequate Schirmer test results.
Why Surgery Worsens Meibomian Gland Dysfunction
Cataract Surgery
Cataract surgery, despite being one of the most successful procedures in medicine, consistently induces or exacerbates MGD and dry eye symptoms.[1][2][3][12] Multiple mechanisms contribute to this phenomenon:
- Corneal nerve transection during incision creation disrupts the neural feedback loop that regulates tear production and blinking.[13][5]
- Microscope light exposure and surgical trauma trigger inflammatory cascades on the ocular surface.[7][11]
- Postoperative medications, particularly preserved topical agents, further damage the ocular surface and meibomian glands.[1][5]
- Altered blink dynamics and lid-globe interaction after surgery affect meibomian gland expression.[6][11]
Studies demonstrate that meibomian gland function deteriorates significantly after cataract surgery, with decreased meibum expressibility and quality persisting for months.[7][6] Critically, patients with preoperative MGD experience significantly worse outcomes, with prolonged recovery times and higher rates of persistent symptoms.[14]
The impact on visual outcomes is equally concerning. MGD-related tear film instability causes fluctuating vision and increased higher-order aberrations, undermining the precision of modern biometry and premium intraocular lens performance.[15][16] Recent studies show that preoperative treatment of MGD with intense pulsed light therapy significantly improves both refractive accuracy and contrast sensitivity after cataract surgery.[15][16]
Glaucoma Surgery
Trabeculectomy and other filtering procedures create additional challenges for the ocular surface.[17][18][19] The filtering bleb itself disrupts normal tear film distribution, and patients with functioning blebs demonstrate significantly higher rates of DED compared to controls.[19] Bleb height and the presence of microcysts correlate directly with tear film instability and corneal staining.[19]
However, there is a silver lining: successful glaucoma surgery that eliminates the need for preserved topical medications can actually improve ocular surface parameters compared to the fellow eye receiving continued medical therapy.[20] This underscores the toxic effects of chronic antiglaucoma medication use on meibomian glands and the ocular surface.[17][18]
Retina Surgery and Vitrectomy
Vitreoretinal surgery significantly impacts the ocular surface through multiple mechanisms.[21][22][23] Studies using in vivo confocal microscopy demonstrate dramatic reductions in corneal nerve fiber density that persist for at least one year after surgery.[23] This denervation contributes to decreased tear production, altered blink reflexes, and impaired meibomian gland function.
The effects are particularly pronounced when vitrectomy is combined with phacoemulsification and gas or silicone oil tamponade.[23] Patients experience increased inflammatory cytokines, reduced tear break-up time, and worsened MGD parameters that may take months to resolve.[21][22] Importantly, molecular markers of dry eye are present even when clinical signs are subtle, suggesting subclinical ocular surface damage in many patients.[21]
Pterygium Surgery
Pterygium itself is strongly associated with MGD, with up to 88% of pterygium patients demonstrating meibomian gland alterations on meibography.[24] Remarkably, the location of meibomian gland loss often corresponds to the side of the pterygium, suggesting a direct mechanical relationship.[25][26][24]
Surgical excision of pterygium can improve dry eye symptoms and tear film parameters, including meibomian gland dropout.[27][28] However, the preoperative MGD must be recognized and addressed to optimize outcomes and prevent postoperative complications.
Eyelid Surgery and Blepharoplasty
Upper eyelid surgery presents unique challenges for the ocular surface.[29][30][31] While most studies show that dry eye symptoms improve or remain stable after blepharoplasty, temporary worsening is common in the early postoperative period.[29] Patients with pre-existing dry eye are at higher risk for persistent symptoms.[30]
Interestingly, when upper blepharoplasty is combined with ptosis repair (particularly Müller muscle-conjunctival resection), the risk of worsening dry eye increases significantly.[29] This highlights the importance of preoperative assessment and patient counseling regarding realistic expectations.
The Power of Meibography: Seeing What Clinical Examination Misses
Meibography—infrared imaging of the meibomian glands—has revolutionized our ability to diagnose and quantify MGD.[9][32][33] This noninvasive technique allows direct visualization of gland structure, revealing dropout, shortening, dilation, and distortion that are invisible on slit-lamp examination alone.[9][33]
The diagnostic value of meibography is substantial. Studies demonstrate that meibography has high sensitivity (96.7%) and specificity (85%) for diagnosing MGD.[34] Importantly, meibomian gland morphology is a sensitive early indicator of dysfunction, often revealing abnormalities before patients develop symptoms or before standard clinical tests become abnormal.[34]
This is critical for surgical planning. Patients may have severe meibomian gland atrophy with compensatory mechanisms (increased aqueous production, gland dilation) that mask the underlying problem.[34] These compensatory mechanisms fail under the stress of surgery, leading to the sudden onset of severe symptoms postoperatively.
Meibography as a Screening Tool
The case for routine preoperative meibography is compelling:
1. Objective documentation of baseline gland status allows for informed surgical planning and realistic patient expectations.[9][32][33]
2. Risk stratification identifies patients who require preoperative optimization before proceeding with elective surgery.[2][12][14]
3. Treatment monitoring enables assessment of therapeutic interventions before surgery.[7]
4. Medicolegal protection provides objective evidence of preoperative counseling and appropriate management.[2]
The Evidence for Preoperative Optimization
Multiple randomized controlled trials demonstrate that preoperative treatment of MGD significantly improves surgical outcomes.[7][35] A landmark study by Song et al. showed that patients who received preoperative MGD treatment (warm compresses, lid hygiene, and anti-inflammatory therapy) had significantly better outcomes at one and three months after cataract surgery compared to those who received only postoperative treatment.[7]
The benefits of preoperative optimization include:
- Reduced symptom severity and faster resolution of postoperative dry eye[7][35]
- Better tear film stability with higher tear break-up times[7]
- Improved meibomian gland function with better meibum quality and expressibility[7][35]
- Enhanced visual outcomes with reduced higher-order aberrations and better contrast sensitivity[15][16]
- Greater refractive accuracy with more reliable biometry measurements[16]
The Pediatric Time Bomb: Screen Time and Meibomian Gland Atrophy
Perhaps the most alarming development in MGD research is the recognition of severe meibomian gland atrophy in children and adolescents, strongly associated with excessive electronic screen use.[36]
In our published study in the American Journal of Ophthalmology, we demonstrated that children with severe meibomian gland atrophy (≥grade 2) had dramatically higher electronic screen use than controls.[36] Eighty-six percent of children with severe atrophy reported ≥4 hours of daily screen time, and 50% reported ≥8 hours—while no controls exceeded 2 hours.[36] The association was dose-dependent: increased screen time correlated with worse meibography grades (odds ratio 2.74).[36]
The clinical consequences were severe. All children with significant meibomian gland atrophy had symptomatic dry eye disease, and many had corneal neovascularization (29%), visual acuity loss (41%), and even central corneal neovascularization (14%)—findings typically seen in severe adult dry eye.[36]
The Future Surgical Implications
This pediatric epidemic has profound implications for future surgical outcomes. These children, now with severely depleted meibomian glands, will eventually require cataract surgery, refractive surgery, glaucoma surgery, or other ocular procedures. With fewer functional glands remaining, their capacity to maintain ocular surface homeostasis after surgical stress will be severely compromised.
Recovery times will be prolonged, symptom severity will be greater, and the risk of chronic postoperative dry eye will be substantially elevated. The compensatory mechanisms that allow young patients to tolerate ocular surface stress will be exhausted before they reach middle age.
Additionally, our study revealed that 62.5% of children with severe meibomian gland atrophy tested positive for autoimmune disease biomarkers, despite having no systemic symptoms.[36] This suggests that meibography may serve as an early diagnostic indicator for autoimmune disease, potentially allowing intervention before systemic manifestations develop.[36]
Clinical Recommendations: A New Standard of Care
Based on the overwhelming evidence, the following approach should be considered standard of care for all patients undergoing ocular surgery:
Preoperative Assessment
1. Comprehensive dry eye evaluation including symptom questionnaires (OSDI, SPEED), tear break-up time, corneal staining, and Schirmer testing[2][3][12]
2. Meibography of all four eyelids with standardized grading and documentation[9][32][33]
3. Meibomian gland expression assessment evaluating both quality and expressibility of meibum[7][6]
4. Risk stratification based on meibography findings, symptoms, and planned procedure[2][12]
Preoperative Optimization
For patients with moderate to severe MGD:
1. Delay elective surgery until ocular surface is optimized[1][2][12]
2. Implement MGD treatment including warm compresses, lid hygiene, omega-3 supplementation, and anti-inflammatory therapy[7][35]
3. Consider advanced therapies such as intense pulsed light, thermal pulsation, or intraductal probing for severe cases[9][15][16]
4. Reassess with repeat meibography to document improvement before proceeding[7]
Intraoperative Modifications
1. Minimize incision size and surgical trauma[1][5]
2. Limit microscope light exposure to reduce phototoxicity[1]
3. Use preservative-free medications exclusively[1][5]
4. Avoid aspirating specula that can damage meibomian glands[1]
Postoperative Management
1. Continue preservative-free regimens for all topical medications[1][5]
2. Limit exposure to epitheliotoxic agents (antibiotics, NSAIDs)[1]
3. Maintain MGD therapy throughout the postoperative period[7][35]
4. Monitor with objective testing including repeat meibography when indicated[7]
Medicolegal Considerations
The medicolegal implications of undiagnosed MGD are significant. Patients who develop severe postoperative dry eye symptoms often believe their surgery was performed incorrectly, leading to complaints, poor reviews, and potential litigation. When the true cause—pre-existing MGD exacerbated by surgery—is not documented preoperatively, defending against these claims becomes difficult.
Preoperative meibography provides objective documentation that:
1. The patient had pre-existing gland pathology
2. The patient was appropriately counseled about risks
3. Reasonable steps were taken to optimize the ocular surface
4. Postoperative symptoms are a known consequence of the underlying disease, not surgical error
This documentation is invaluable when patients claim their symptoms are "new" or "caused by the surgery."
Conclusion: A Paradigm Shift in Surgical Preparation
The evidence is clear: meibomian gland dysfunction is a critical determinant of surgical outcomes across all subspecialties of ophthalmology. The oil layer produced by these glands is essential for visual quality, ocular comfort, and patient satisfaction. Yet MGD remains dramatically underdiagnosed and undertreated in the preoperative setting.
Meibography has emerged as an essential tool for identifying at-risk patients and guiding preoperative optimization. The technology is noninvasive, objective, and increasingly accessible. The evidence supporting preoperative MGD treatment is robust, with multiple randomized trials demonstrating significant benefits.
The pediatric epidemic of screen-related meibomian gland atrophy adds urgency to this issue. We are creating a generation of patients with severely compromised ocular surface reserve who will face greater surgical risks and prolonged recovery times throughout their lives.
It is time for a paradigm shift in how we prepare patients for ocular surgery. Meibography should be as routine as biometry before cataract surgery. MGD should be treated as aggressively as we treat preoperative inflammation or infection. And patients should be counseled that ocular surface optimization is not optional—it is essential for achieving the excellent outcomes they expect and deserve.
The hidden epidemic of meibomian gland dysfunction can no longer remain hidden. Our patients' vision—and their trust—depends on our willingness to see it.
The chapter above provides a comprehensive, evidence-based discussion of why meibomian gland assessment and meibography are critical before all types of ocular surgery. The document synthesizes current literature with your published research on pediatric screen time and meibomian gland atrophy, emphasizing the long-term implications for surgical outcomes.
The chapter addresses all the surgical subspecialties you mentioned (cataract, cornea/pterygium, glaucoma, retina, and eyelid surgery) and explains why the most common postoperative complaints—foreign body sensation and blurry vision—are often due to meibomian gland dysfunction rather than surgical complications. The discussion of your pediatric study highlights the concerning future implications for children with severe gland atrophy who will eventually need surgery.
The evidence demonstrates that preoperative MGD treatment significantly improves surgical outcomes across multiple procedures, and that meibography provides critical diagnostic information that clinical examination alone cannot reveal.[7][35][15][16][9][32][33][34] The chapter makes a compelling case for routine preoperative meibography as a new standard of care, supported by robust clinical trial data and practical medicolegal considerations.
Would you like me to expand any particular section or adjust the tone and emphasis of specific portions of the chapter?
References
1. Preventing and Managing Iatrogenic Dry Eye Disease During the Entire Surgical Pathway: A Study Focusing on Patients Undergoing Cataract Surgery. Giannaccare G, Barabino S, Di Zazzo A, Villani E. Journal of Clinical Medicine. 2024;13(3):748. doi:10.3390/jcm13030748.
2. Call to Action: Treating Dry Eye Disease and Setting the Foundation for Successful Surgery. Donaldson K, Parkhurst G, Saenz B, et al. Journal of Cataract and Refractive Surgery. 2022;48(5):623-629. doi:10.1097/j.jcrs.0000000000000844.
3. Management of Cataract in Dry Eye Disease: Preferred Practice Pattern Guidelines. Donthineni PR, Deshmukh R, Ramamurthy C, et al. Indian Journal of Ophthalmology. 2023;71(4):1364-1372. doi:10.4103/IJO.IJO_2807_22.
4. Ocular Surface Changes Associated With Ophthalmic Surgery. Mikalauskiene L, Grzybowski A, Zemaitiene R. Journal of Clinical Medicine. 2021;10(8):1642. doi:10.3390/jcm10081642.
5. TFOS DEWS II Iatrogenic Report. Gomes JAP, Azar DT, Baudouin C, et al. The Ocular Surface. 2017;15(3):511-538. doi:10.1016/j.jtos.2017.05.004.
6. Evaluation of Dry Eye and Meibomian Gland Dysfunction After Cataract Surgery. Han KE, Yoon SC, Ahn JM, et al. American Journal of Ophthalmology. 2014;157(6):1144-1150.e1. doi:10.1016/j.ajo.2014.02.036.
7. Preoperative Management of MGD Alleviates the Aggravation of MGD and Dry Eye Induced by Cataract Surgery: A Prospective, Randomized Clinical Trial. Song P, Sun Z, Ren S, et al. BioMed Research International. 2019;2019:2737968. doi:10.1155/2019/2737968.
8. Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction. Foulks GN, Nichols KK, Bron AJ, et al. Ophthalmology. 2012;119(10 Suppl):S1-12. doi:10.1016/j.ophtha.2012.06.064.
9. Latest Evidences on Meibomian Gland Dysfunction Diagnosis and Management. Villani E, Marelli L, Dellavalle A, Serafino M, Nucci P. The Ocular Surface. 2020;18(4):871-892. doi:10.1016/j.jtos.2020.09.001.
10. Meibomian Gland Dysfunction and Blepharitis: A Common and Still Unsolved Ophthalmic Problem. Kudasiewicz-Kardaszewska A, Grant-Kels JM, Grzybowski A. Clinics in Dermatology. 2023 Jul-Aug;41(4):491-502. doi:10.1016/j.clindermatol.2023.08.005.
11. Observation of Influence of Cataract Surgery on the Ocular Surface. Park Y, Hwang HB, Kim HS. PloS One. 2016;11(10):e0152460. doi:10.1371/journal.pone.0152460.
12. Optimizing the Ocular Surface Prior to Cataract Surgery. He X, Huang AS, Jeng BH. Current Opinion in Ophthalmology. 2022;33(1):9-14. doi:10.1097/ICU.0000000000000814.
13. Ocular Surface Disease Following LASIK and Cataract Surgery: A Review of Their Interrelated Complications. Spangler MD, Kirupaharan N, Sheppard JD. Frontiers in Medicine. 2025;12:1623324. doi:10.3389/fmed.2025.1623324.
14. Upper Eyelid Meibomian Gland Dysfunction Is a Risk Factor for Dry Eye Symptoms Following Cataract Surgery in the Early Phase. Fujimoto H, Ochi S, Inoue Y, Kiryu J. Clinical Ophthalmology (Auckland, N.Z.). 2022;16:293-302. doi:10.2147/OPTH.S346606.
15. Dry Eye Treatment With Intense Pulsed Light for Improving Visual Outcomes After Cataract Surgery With Diffractive Trifocal Intraocular Lens Implantation. Teshigawara T, Akaishi M, Mizuki Y, et al. Journal of Clinical Medicine. 2024;13(22):6973. doi:10.3390/jcm13226973.
16. Effect of Preoperative Dry Eye Treatment With Intense Pulsed Light With Meibomian Gland Expression on the Refractive Accuracy of Cataract Surgery in Patients With Meibomian Gland Dysfunction-Related Dry Eye: A Single-Center, Prospective, Open-Label Study. Kawagoe T, Mizuki Y, Akaishi M, et al. Journal of Clinical Medicine. 2025;14(8):2805. doi:10.3390/jcm14082805.
17. Glaucoma and Dry Eye Disease: Opportunity to Assess and Treat. Nijm LM, Schweitzer J, Gould Blackmore J. Clinical Ophthalmology (Auckland, N.Z.). 2023;17:3063-3076. doi:10.2147/OPTH.S420932.
18. Ocular Surface Disease in Glaucoma Patients. Scelfo C, ElSheikh RH, Shamim MM, et al. Current Eye Research. 2023;48(3):219-230. doi:10.1080/02713683.2022.2041041.
19. Dry Eye Disease in Patients With Functioning Filtering Blebs After Trabeculectomy. Ji H, Zhu Y, Zhang Y, et al. PloS One. 2016;11(3):e0152696. doi:10.1371/journal.pone.0152696.
20. Inter-Eye Comparison of the Ocular Surface of Glaucoma Patients Receiving Surgical and Medical Treatments. Romano D, De Ruvo V, Fogagnolo P, Farci R, Rossetti LM. Journal of Clinical Medicine. 2022;11(5):1238. doi:10.3390/jcm11051238.
21. Altered Mucins and Aquaporins Indicate Dry Eye Outcome in Patients Undergoing Vitreo-Retinal Surgery. Mani R, Shobha PS, Thilagavathi S, et al. PloS One. 2020;15(5):e0233517. doi:10.1371/journal.pone.0233517.
22. Ocular Surface Changes Following Vitreoretinal Procedures. Venkatesh R, Jayadev C, Mangla R, et al. Indian Journal of Ophthalmology. 2023;71(4):1123-1126. doi:10.4103/IJO.IJO_2573_22.
23. Alterations in the Ocular Surface and Corneal Subbasal Nerve Plexus Following Various Retinal Surgical Procedures: A One-Year Confocal Microscopy Prospective Study. Wei Q, Niu L, Zhou X, Chen H, Jiang R. Clinical Ophthalmology (Auckland, N.Z.). 2024;18:1143-1155. doi:10.2147/OPTH.S456631.
24. Impact of Pterygium on the Ocular Surface and Meibomian Glands. Wanzeler ACV, Barbosa IAF, Duarte B, et al. PloS One. 2019;14(9):e0213956. doi:10.1371/journal.pone.0213956.
25. The Influence of Pterygium on Meibomian Glands and Dry Eye Parameters. Devebacak A, Teker ME, Palamar M. Optometry and Vision Science : Official Publication of the American Academy of Optometry. 2023;100(3):207-210. doi:10.1097/OPX.0000000000001996.
26. Meibomian Gland Dysfunction Correlates to the Tear Film Instability and Ocular Discomfort in Patients With Pterygium. Wu H, Lin Z, Yang F, et al. Scientific Reports. 2017;7:45115. doi:10.1038/srep45115.
27. Systematic Review: Effects of Pterygium and Pingueculum on the Ocular Surface and Efficacy of Surgical Excision. Linaburg T, Choi D, Bunya VY, Massaro-Giordano M, Briceño CA. Cornea. 2021;40(2):258-267. doi:10.1097/ICO.0000000000002575.
28. Postoperative Outcomes Regarding Tear Film Changes and Dry Eye Symptoms in Primary Pterygium Excision With Conjunctival Autograft. Zatarain-Barrón NC, Vera-Duarte GR, Flores NM, et al. Eye & Contact Lens. 2025;51(4):186-189. doi:10.1097/ICL.0000000000001178.
29. Health-Related Quality-of-Life Outcomes for Upper Blepharoplasty and Blepharoptosis Surgery: A Report by the American Academy of Ophthalmology. Vagefi MR, Aakalu VK, Foster JA, et al. Ophthalmology. 2025;:S0161-6420(25)00448-8. doi:10.1016/j.ophtha.2025.07.014.
30. Changes of Dry Eye Related Markers and Tear Inflammatory Cytokines After Upper Blepharoplasty. Zhao S, Song N, Gong L. Frontiers in Medicine. 2021;8:763611. doi:10.3389/fmed.2021.763611.
31. Impact of Upper Blepharoplasty, With or Without Orbicularis Oculi Muscle Removal, on Tear Film Dynamics and Dry Eye Symptoms: A Randomized Controlled Trial. Hollander MHJ, Pott JWR, Delli K, et al. Acta Ophthalmologica. 2022;100(5):564-571. doi:10.1111/aos.15036.
32. Meibography: A Japanese Perspective. Arita R. Investigative Ophthalmology & Visual Science. 2018;59(14):DES48-DES55. doi:10.1167/iovs.17-23631.
33. Validity of Noninvasive Meibography Systems: Noncontact Meibography Equipped With a Slit-Lamp and a Mobile Pen-Shaped Meibograph. Arita R. Cornea. 2013;32 Suppl 1:S65-70. doi:10.1097/ICO.0b013e3182a2c7c6.
34. Meibomian Gland Morphology Is a Sensitive Early Indicator of Meibomian Gland Dysfunction. Adil MY, Xiao J, Olafsson J, et al. American Journal of Ophthalmology. 2019;200:16-25. doi:10.1016/j.ajo.2018.12.006.
35. Clinical Efficacy of Eyelid Hygiene in Blepharitis and Meibomian Gland Dysfunction After Cataract Surgery: A Randomized Controlled Pilot Trial. Eom Y, Na KS, Hwang HS, et al. Scientific Reports. 2020;10(1):11796. doi:10.1038/s41598-020-67888-5.
36. New Indicator of Children's Excessive Electronic Screen Use and Factors in Meibomian Gland Atrophy. Cremers SL, Khan ARG, Ahn J, et al. American Journal of Ophthalmology. 2021;229:63-70. doi:10.1016/j.ajo.2021.03.035.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.